Bimzelx

Pharma

With win over AbbVie's Skyrizi, UCB's Bimzelx remains undefeated

UCB's IL-17 inhibitor Bimzelx has topped Skyrizi, as a phase 3b study of patients with active psoriatic arthritis has achieved its primary endpoint.

Kevin Dunleavy Mar 11, 2026 11:29am

UCB sign

UCB reaps the rewards of fast-growing Bimzelx

Feb 27, 2026 11:51am

UCB sign

Fast-rising UCB scores FDA nod for rare disease drug Kygevvi

Nov 4, 2025 11:36am

UCB sign

UCB extends Bimzelx campaign after hidradenitis suppurativa nod

Jul 8, 2025 11:33am

Dr. Pimple Popper joins UCB hidradenitis suppurativa campaign

Apr 24, 2025 12:46pm

drug launch drug launches

UCB's Bimzelx outpacing AbbVie's Rinvoq, Skyrizi on awareness

Feb 14, 2025 9:20am